Specific Indications for Different Classes of Phenothiazines

Archives of General Psychiatry

Volumn 30, Issue 1, 1974, Pages 94-99

  Hollister, Leo E ^a   Kimbell, Isham ^b   Pokorny, Alex ^b  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b Veterans Administration   (United States)

^c UNIVERSITY OF TEXAS MEDICAL BRANCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHLORPROMAZINE; FLUPHENAZINE; NEUROLEPTIC AGENT; PERPHENAZINE; PHENOTHIAZINE DERIVATIVE; THIORIDAZINE;

ADULT; AGE; ARTICLE; CLASSIFICATION; CLINICAL TRIAL; DRUG SCREENING; HOSPITALIZATION; HUMAN; PARANOID SCHIZOPHRENIA; PSYCHOLOGY; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; REMISSION; SCHIZOPHRENIA;

ADULT; AGE FACTORS; ANTIPSYCHOTIC AGENTS, PHENOTHIAZINE; CHLORPROMAZINE; CLINICAL TRIALS; DRUG EVALUATION; FLUPHENAZINE; HOSPITALIZATION; HUMAN; PERPHENAZINE; PHENOTHIAZINES; PSYCHIATRIC STATUS RATING SCALES; REMISSION, SPONTANEOUS; SCHIZOPHRENIA; SCHIZOPHRENIA, PARANOID; SCHIZOPHRENIC PSYCHOLOGY; THIORIDAZINE;

EID: 0016016777     PISSN: 0003990X     EISSN: 15383636     Source Type: Journal    
DOI: 10.1001/archpsyc.1974.01760070072011     Document Type: Article

References (14)

1. Overall JE, Hollister LE: Decisions about drug treatment: II. Expert opinion in a hypothetical situation. Behav Sci 17:349-360, 1972.
2. Overall JE, Henry BW: Decisions about drug treatment: III. Selection of treatment for psychiatric inpatients. Arch Gen Psychiatry 28:81-89, 1973.
3. Overall JE, Klett CJ: Applied multivariate analysis. New York, McGraw-Hill Book Co Inc, 1973.
4. Hollister LE, et al: Specific therapeutic actions of acetophenazine, perphenazine and benzquinamide in newly admitted schizophrenic patients. Clin Pharmacol Therap 8:249-255, 1967.
5. Overall JE, Hollister LE, Pichot P: Major psychiatric disorders: A four-dimensional model. Arch Gen Psychiatry 16:146-151, 1967.
6. Shaffer JP: Defining and testing hypotheses in multi-dimensional contingency tables. Psychol Bull 79:127-141, 1973.
7. Kimbell I Jr, et al: Comparison of thioridazine and chlorpromazine in doctor's choice research design. Clin Pharmacol Ther 12:825-832, 1971.
8. Tupin JP, Overall JE: Further investigation of factors affecting outcome in a doctor's choice treatment setting. Dis Nerv Syst 31:684-694, 1970.
9. Henry BW, Overall JE, Markette JR: Comparison of major drug therapies for alleviation of anxiety and depression. Dis Nerv Syst 32:657-667, 1971.
10. Casey JF, et al: Treatment of schizophrenic reactions with phenothiazine derivatives: A comparative study of chlorpromazine, triflupromazine, mepazine, prochlorperazine, perphenazine, and phenobarbital. Am J Psychiatry 117:97-105, 1960.
11. Lasky JJ, et al: Drug treatment of schizophrenic patients: A comparative evaluation of chlorpromazine, chlorprothixene, fluphenazine, reserpine, thioridazine, and triflupromazine. Dis Nerv Syst 23:698, 1962.
12. National Institute of Mental Health-Psychopharmacology Service Center Collaborative Study Group: Phenothiazine treatment in acute schizophrenia. Arch Gen Psychiatry 10:246, 1964.
13. Galbrecht CR, Klett CJ: Predicting response to phenothiazines: The right drug for the right patient. J Nerv Ment Dis 147:173-183, 1968.
14. Goldberg SC, et al: Prediction of response to phenothiazines in schizophrenia: A crossvalidation study. Arch Gen Psychiatry 26:367-373, 1972.